T. Vaysse

发表

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

A. Amiot, B. Bonaz, H. Sokol, 2018, Alimentary pharmacology & therapeutics.

Three‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi‐centre cohort study

A. Amiot, G. Savoye, L. Peyrin-Biroulet, 2019, Alimentary pharmacology & therapeutics.

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

A. Amiot, B. Bonaz, H. Sokol, 2017, Alimentary pharmacology & therapeutics.

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

A. Amiot, G. Savoye, L. Peyrin-Biroulet, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study

A. Amiot, H. Sokol, B. Flourié, 2017, Alimentary pharmacology & therapeutics.

P140 Use of vedolizumab in a transplanted liver patient: a case report of the first experience in a liver transplant referral center in Argentina.

J. D. de Paula, F. Carbonnel, M. J. Etchevers, 2017, Journal of Crohn's & colitis.

DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID.

A. Amiot, L. Peyrin-Biroulet, P. Marteau, 2017, Journal of Crohn's & colitis.

F. Carbonnel, M. Ebbo, N. Schleinitz, 2017, Annals of Internal Medicine.